CClinicalTrials.gg
RecruitingNCT07564960Updated Sep 21, 2026

Social Optimization Study

An interventional study of Social support receptivity training and Social awareness training in Lung Cancer, sponsored by University of Arizona. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by University of Arizona · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This study tests whether clinical interventions to optimize support receptivity lead to improvements in social integration and quality of life (QOL) amongst long-term lung cancer survivors. The feasibility and acceptability of the intervention and assessment procedures will be examined. Thirty long-term lung cancer survivors will be randomized to a support receptivity intervention or an attention-control condition. Our intervention draws on cognitive behavioral therapy (CBT) strategies to reduce social anxiety, improve social awareness, and promote social integration. We will use two novel in vivo sampling methods using a mobile phone platform to assess social engagement and QOL improvements: 1) recording via the Electronically Activated Recorder to capture daily social interactions, and 2) repeated self-report sampling where participants answer questions about their social engagement experiences via their personal cell phone.

Read the detailed description

The growing cancer survivorship population. This year, more than 1.77 million Americans will receive a life-altering cancer diagnosis. Fortunately, improvements in early detection and care have led to dramatic increases in survival. Over 18 million Americans or 5.4% of the total U.S. population now identify as cancer survivors with an expected growth to 26 million by 2040. Recognition of these immense changes in survival has led the National Cancer Institute (NCI) to found the Office of Cancer Survivorship (OCS) with a stated goal of "enhancing the quality and length of survival of all persons diagnosed with cancer…" Consistent with its mission, NCI/OCS is prioritizing research that improves the QOL of this growing survivorship population.

Social integration is a critical moderator. Social integration is one potential resilience factor that may be key to improving QOL among cancer survivors. Social integration, the degree of social embeddedness and strength of social ties, is amongst the most robust predictors of a broad range of mental and physical health outcomes. Robust, replicated research documents that people who are more socially integrated experience lower rates of depression, anxiety, and most forms of chronic illness and experience lower age-adjusted disease-specific and all-cause mortality. Decades of research show that interventions to provide more support including via support groups, community events, or provision of supportive persons can improve mental and physical health outcomes. At the same time, the improvements in these outcomes are modest, suggesting that not all relevant factors are accounted for.

Work from our team examining Hispanic advantages in mental and physical health via culturally moderated social integration suggest that support receptivity is a key element of social integration effectiveness. This revelation suggests that social integration is an interactive process not unlike effective neuronal communication. Neuron communication is moderated by both the adequacy of the signal and the sensitivity of the receptor. Both must be effective for transmission to take place. Social integration benefits may work the same way. While nearly all social integration interventions have focused on providing sufficient support, almost no interventions have sought to enhance support receptivity to enhance social integration effects in the context of physical health such as cancer survivorship.

The current goal is to test whether clinical interventions to optimize support receptivity lead to improvements in social integration and QOL amongst cancer survivor populations. A pilot randomized clinical trial is proposed to evaluate feasibility and acceptability of the intervention and assessment procedures, and to explore whether the intervention can improve QOL through optimizing survivors' social receptivity to determine proof-of-concept. We propose to enroll 30 long-term (> 12 months post-treatment) lung cancer survivors randomized to either a support receptivity intervention or attention-control condition. Our intervention draws on the large body of cognitive behavioral therapy (CBT) interventions to reduce social anxiety, improve social awareness, and promote social integration for a wide range of mental health conditions. The proposed 3-week, 6 session CBT intervention specifically targets cognitive awareness of prosocial cues coupled with Behavioral Activation and Social Skills Training to improve target person social engagement. Building on our ongoing, NCI-funded work on social engagement in lung cancer patients, we will use two novel in vivo sampling methods using a mobile phone platform to assess social engagement and QOL improvements: 1) recording via the Electronically Activated Recorder (EAR)17 to capture frequency of daily social interactions, and 2) repeated self-report sampling (ecological momentary assessments) where participants will be prompted to answer questions about their social engagement experiences via their personal cell phone.

The following aims are proposed:

Aim 1: Explore whether a CBT intervention targeting social receptivity can improve QOL in cancer survivors compared to an attention control condition to determine proof-of-concept. Hypothesis: We expect that the intervention will produce improvements via the targeted mechanism with sustained differences at 2 months post.

Aim 2: Explore the degree to which the CBT intervention increases objectively assessed social engagement as a putative mechanism. Hypothesis: We expect to demonstrate proof-of-concept that social engagement is malleable with implications for survivor mental and social health in alignment with NCI survivorship priorities.

02

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • Social support
  • Psycho-oncology
  • Lung neoplasms
03

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Adults (18 Years or Older)
  2. History of lung cancer
  3. at least 12 months since cancer diagnosis
  4. fluent in English
  5. able to attend virtually or in person sessions at the University of Arizona.

Exclusion criteria

Exclusion Criteria:

  1. Less than 12 months of cancer diagnosis at time of enrollment
  2. undergoing treatment for mood or anxiety health issues at time of enrollment
  3. unable to provide informed consent.
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Social support receptivity training

    Participants will receive a 3-week, 6 session CBT intervention targeting cognitive awareness of prosocial cues coupled with behavioral activation and social skills training to improve target person social engagement.

    Behavioral: Social support receptivity training

  • Active comparator
    Social awareness training

    Participants receiving a 3-week, 6 session program designed to increase awareness of the social support already available to them.

    Behavioral: Social awareness training

Interventions

  • BehavioralSocial support receptivity training

    A 3-week, 6-session CBT intervention that targets cognitive awareness of prosocial cues and leverages behavioral activation and social skills training

  • BehavioralSocial awareness training

    A 3-week, 6 session program designed to increase awareness of available social support.

05

What researchers measure

Primary outcomes

  1. Feasibility assessed by recruitment and retention rates

    Given the pilot nature of this work, the intervention/study will be deemed feasible if 20% of eligible potential participants approached enroll and 50% of enrolled participants are retained at post-intervention

    Time frame: Throughout the recruitment period

  2. Acceptability assessed by study-specific survey after the intervention

    The intervention/study will be deemed acceptable if, on average, participants report satisfaction with the overall program/study as ≥2 on a 0-4 scale.

    Time frame: 3 weeks - immediately after the intervention

Secondary outcomes

  1. Change in quality of life (QOL) using the SF-36 from baseline to immediately after the intervention.

    Participants will complete the 36-item SF-36, which evaluates eight health domains-physical functioning, pain, vitality, social functioning, and mental health-covering physical and mental components. Scores on each domain range from 0-100, with higher scores indicating better quality of life (QOL).

    Time frame: 3 weeks - immediately after the intervention

  2. Change in Perceived Stress using the Perceived Stress Scale (PSS) from baseline to immediately after the intervention

    Participants will complete a 10-item PSS, which evaluates an individual's stress level. Scores range from 0-40, with higher scores indicating higher perceived stress.

    Time frame: 3 weeks - immediately after the intervention

  3. Change in depression using the CES-D scale from baseline to immediately after the intervention

    Participants will complete a 10-item CES-D, which evaluates an individual's self-reported symptoms of depression. The total score is calculated by totaling all items scored after reversing the positive mood items. Possible range for scores is 0-11 with higher scores representing greater degrees of depressed mood.

    Time frame: 3 weeks - immediately after the intervention

  4. Change in network diversity using the Berkman-Syme Social Network Index (BS-SNI) from baseline to immediately after the intervention

    Participants will complete the BS-SNI, which assesses network diversity, and the number of people in an individual's network.

    Time frame: 3 weeks - immediately after the intervention

  5. Change in subject loneliness and social isolation using the UCLA-Loneliness Scale from baseline to immediately after the intervention

    Participants will complete the 10-item UCLA Loneliness Scale, which measures subjective loneliness and social isolation. Higher scores represent higher levels of loneliness.

    Time frame: 3 weeks - immediately after the intervention

  6. Change in Multidimensional Scale of Perceived Social Support (MSPSS) scores from baseline to immediately after the intervention

    Participants will complete a 12-item MSPSS, which measures an individual's perception of support. A sum through all scores can range from 12-84, with higher scores noting a higher perceived support.

    Time frame: 3 weeks - immediately after the intervention

06

Study locations

1 of 1 sites recruiting
  • University of Arizona Mel and Enid Zuckerman College of Public Health
    Tucson, Arizona 85719, United States
    • Francis Morales-Lozada · Contact · fmoraleslozada@arizona.edu · 520-621-0563
    • Scott Carvajal, PhD, MPH · Principal investigator
    • John Ruiz, PhD · Sub investigator
    • Matthias Mel, PhD · Sub investigator
    • Linda Garland, MD · Sub investigator
    • Rina Fox, PhD, MPH · Sub investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07564960
Lead sponsor
University of Arizona
Responsible party
Sponsor
First posted
May 4, 2026
Start date
Apr 27, 2026
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Sep 21, 2026

Study contacts

Francis Morales-Lozada
Contact
fmoraleslozada@arizona.edu
(520) 621-0563
Scott Carvajal, PhD, MPH
principal investigator · University of Arizona

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion